<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323800</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00245634</org_study_id>
    <nct_id>NCT04323800</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma to Stem Coronavirus (CSSC-001)</brief_title>
  <acronym>CSSC-001</acronym>
  <official_title>Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control
      (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day
      28.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, controlled, double-blinded phase 2 trial will assess the efficacy and safety
      of Anti- SARS-CoV-2 convalescent plasma as prophylaxis following exposure to COVID-19 (as
      defined in the inclusion criteria). Adults 18 years of age and older with high risk exposure
      as defined by CDC may participate. A total of 500 eligible subjects will be randomized in a
      1:1 ratio to receive either high titer anti-SARS-CoV-2 plasma or control (SARS-CoV-2
      non-immune plasma).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Comparison of proportions of cumulative incidence of development of SARS-Cov-2 infection (symptoms compatible with infection and/or + molecular testing) regardless of disease severity, following high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to COVID-19.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Cumulative incidence of serious adverse events categorized separately as either severe infusion reactions and Acute Respiratory Distress Syndrome during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Cumulative incidence of grade 3 and 4 adverse events during the study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of disease severity</measure>
    <time_frame>up to Day 28</time_frame>
    <description>Cumulative incidence of disease severity between the anti-SARS-CoV-2 convalescent plasma and control groups after individuals develop SARS-CoV-2 infection. Severity of disease will be measured using a clinical event scale of disease severity (evaluated up to Day 28):
Death
Requiring mechanical ventilation and/or in ICU
non-ICU hospitalization, requiring supplemental oxygen;
non-ICU hospitalization, not requiring supplemental oxygen;
Not hospitalized, but with clinical and laboratory evidence of COVID-19 infection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-SARS-CoV-2 titers Day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day -1 or day 0 (baseline).</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-SARS-CoV-2 titers Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day 1.</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-SARS-CoV-2 titers Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day 7.</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-SARS-CoV-2 titers Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day 14.</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-SARS-CoV-2 titers Day 90</measure>
    <time_frame>Day 90</time_frame>
    <description>Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day 90.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rates of SARS-CoV-2 PCR positivity</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Compare the rates of SARS-CoV-2 PCR positivity (RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of SARS-CoV-2 PCR positivity</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Compare the duration (days) of SARS-CoV-2 PCR positivity (RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak quantity levels of SARS-CoV-2 RNA</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Compare the peak quantity levels of SARS-CoV-2 RNA amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 1, 7, 14 and 28 days.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronavirus</condition>
  <condition>Convalescence</condition>
  <arm_group>
    <arm_group_label>High titer anti-SARS-CoV-2 plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with High titer anti-SARS-CoV-2 plasma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS-CoV-2 non-immune plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with SARS-CoV-2 non-immune plasma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti- SARS-CoV-2 Plasma</intervention_name>
    <description>SARS-CoV-2 convalescent plasma (1 unit; ~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers â‰¥ 1:320</description>
    <arm_group_label>High titer anti-SARS-CoV-2 plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 non-immune Plasma</intervention_name>
    <description>Normal human plasma collected prior to December 2019</description>
    <arm_group_label>SARS-CoV-2 non-immune plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Subjects must be 18 years of age or older.

          2. Close contact* exposure to person with COVID-19 within 96 hours of enrollment (and 120
             hours of receipt of plasma) defined as:

        2.1 Living in the same household as, being an intimate partner of, or providing care in a
        non-healthcare setting (such as a home) for a person with symptomatic laboratory-confirmed
        COVID-19 infection without using recommended precautions for home care and home isolation.

        2.2 HCP who have had prolonged close contact with patients with COVID-19 who were not
        wearing a face mask while HCP nose and mouth were exposed to material potentially
        infectious with the virus causing COVID-19.

        2.3 Being present in the room for procedures that generate aerosols or during which
        respiratory secretions are likely to be poorly controlled (e.g., cardiopulmonary
        resuscitation, intubation, extubation, bronchoscopy, nebulizer therapy, sputum induction)
        on patients with COVID-19 when the healthcare providers' eyes, nose, or mouth were not
        protected.

        Exclusion Criteria

          1. Receipt of any blood product in past 120 days.

          2. Medical, psychiatric,cognitive illness or recreational drug/alcohol use that in the
             opinion of the principal investigator, would affect subject safety and/or compliance.

          3. Symptoms consistent with COVID-19 infection (fevers, acute onset cough, shortness of
             breath) at time of screening.

          4. Laboratory evidence of COVID-19 infection at time of screening.

          5. History or known laboratory evidence of previous COVID-19 infection.

          6. History of prior reactions to transfusion blood products.

          7. inability to complete therapy with the study product within 24 hours after enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shmuel Shoham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shmuel Shoham, MD</last_name>
    <phone>410-614-6702</phone>
    <email>TOID_CRC@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faye Heard</last_name>
      <phone>206-996-4405</phone>
      <email>fhoward@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sonya Heath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leander Lazaro</last_name>
      <phone>858-822-3708</phone>
      <email>llazaro@health.ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Archana Bhatt</last_name>
      <phone>858-822-2661</phone>
      <email>abhatt@health.ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Edward Cachay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Ahn</last_name>
      <phone>310-267-2273</phone>
      <email>JennyAhn@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Judith Currier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Warner</last_name>
      <phone>949-824-1114</phone>
      <email>acwarner@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Don Forthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Menna</last_name>
      <phone>202-444-0357</phone>
      <email>mpm229@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Seble Kassaye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doug Brust</last_name>
      <phone>239-343-8579</phone>
      <email>Exposed2COVID@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Brust, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Adams</last_name>
      <email>BAdams@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Giselle Mosnaim, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaci Miller</last_name>
      <phone>443-481-5738</phone>
      <email>jmiller9@aahs.org</email>
    </contact>
    <investigator>
      <last_name>Barry Meisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JHSPH Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Hammitt</last_name>
      <phone>443-651-0000</phone>
      <email>lhammitt@jhu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carol Tso</last_name>
      <phone>505-722-6372</phone>
      <email>ctso1@jhu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Weatherholtz, BS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thuy Anderson, RN</last_name>
      <phone>443-287-8942</phone>
      <email>tander34@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Shmuel Shoham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Agrillo</last_name>
      <phone>774-455-4456</phone>
      <email>UMassCOVIDplasma@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Gerber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Heininger</last_name>
      <phone>585-273-1926</phone>
      <email>Susanne_Heininger@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Zand, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kohrs</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Moises Huaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifespan/BrownUniversity (Rhode Island Hospital)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Basso</last_name>
      <phone>401-444-2936</phone>
      <email>kristin.basso@lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Jheraldines Paulino</last_name>
      <phone>401-444-3374</phone>
      <email>jheraldines.paulino@lifespan.org</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ayad</last_name>
      <phone>713-704-5198</phone>
      <email>mary.ayad@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Bela Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Convalescence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing is governed by Johns Hopkins University Institutional Guidelines</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

